PRECLINICAL RESEARCH IN HUMAN DRUG DEVELOPMENT by Chitimia, L. et al.
 358 
Bulletin UASVM, Veterinary Medicine 65(1)/2008 
pISSN 1843-5270; eISSN 1843-5378 
 
 
PRECLINICAL RESEARCH IN HUMAN DRUG DEVELOPMENT 
 
Chitimia L., Dana Marin, Elena Drignei 
 
National Medicines Agency, Ministry of Public Health,  
Aviator Sanatescu nr. 48, laurentiu.chitimia@anm.ro 
 
Keywords: ICH guidelines; codification system in preclinical research 
 
Abstract: The paper presents the preclinical research requirements according to the legislation in force and it’s 
implementing guidelines in European Union (EU); tracking down it’s origins to ICH when appropriate. The 
development of any medicinal product requires its research in terms of quality; safety and efficacy. The new 
codification system for ICH guidelines adopted by ICH Steering Committee  is presented in detail. The five 
categories of  CHMP guidelines are explained. The non-clinical research represents a critical stage for the 
transition to studies in humans. The paper supports the researchers in their efforts to assess the needs and the 
timelines in the  preclinical research field.    
 
INTRODUCTION 
 
The development of a medicine before marketing authorization requires its research in 
terms of quality; safety and efficacy; so that only those medicines which are of good quality; 
safe and effective will be available to the general public. The provisions for authorizing 
medicines for marketing purposes through different procedures (national; decentralized; 
mutual recognition and centralized) is contained in Law 95/2006 Title XVII - Medicine; 
which is a implementation of the European Directive 2001/83/EC amended by Directive 
2004/27/EC. In order to clarify and detail the provisions specified in the legislation; the 
Committee for Medicinal Products for Human Use (CHMP) and the International Conference 
on Harmonization (ICH) have adopted scientific guidelines which provide a basis for drug 
research as well as for the practical harmonization of the Member States in interpreting and 
applying those provisions.  
 
MATERIAL AND METHOD 
 
We reviewed the legislation in force and its’ implementing guidelines in European 
Union (EU); tracking down its’ origins to ICH when appropriate.  In the EU; the rules 
governing medicinal products are contained in scientific guidelines prepared by the CHMP; 
which is the scientific body of the European Medicines Agency (EMEA); The need for 
standardization of the requirements to prove that a medicine is suitable for marketing 
authorization leads to the standardization of the research for drug development.  
This standardization; which was referred to as harmonization of regulatory 
requirements was pioneered by the European Community; in the 1980s; followed by the set 
up of ICH at a meeting in Brussels in April 1990. The ICH regions are EU; Japan and USA. 
The main purpose of ICH was to implement a common format for all regions. At the first 
meeting of ICH the topics adopted by the ICH Steering Committee in order to achieve 
harmonization have been divided into Safety; Quality and Efficacy to reflect the three criteria 
which are the basis for authorizing any medicinal product. 
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In November 2005; the ICH Steering Committee adopted a new codification system 
for ICH Guidelines; divided into four major categories: 
Q - "Quality" Topics; i.e. those related to chemical and pharmaceutical Quality 
Assurance (ex: Q1 Stability Testing; Q3 Impurity Testing). 
S - "Safety" Topics; i.e. those related to in vitro and in vivo pre-clinical studies (ex: 
S1 Carcinogenicity Testing; S2 Genotoxicity Testing). 
E - "Efficacy" Topics; i.e. those related to clinical studies in human subject (ex: E4 
Dose Response Studies; Carcinogenicity Testing; E6 Good Clinical Practices) 
M - "Multidisciplinary" Topics; i.e. cross-cutting topics which do not fit uniquely 
into one of the above categories: 
- M1: Medical Terminology (MedDRA)  
- M2: Electronic Standards for Transmission of Regulatory Information (ESTRI)  
- M3: Timing of Pre-clinical Studies in Relation to Clinical Trials  
- M4: The Common Technical Document (CTD)  
- M5: Data Elements and Standards for Drug Dictionaries [1]. 
The first ICH Guideline which dealt with harmonizing of the format of reporting data 
was E3; Content and Format of Clinical Study Reports. This Guideline describes a single 
format for reporting the core clinical studies that make up the clinical section of a registration 
dossier. A target for the first phase of ICH activities was to adopt a single format of submitted 
documentation necessary to demonstrate the quality; safety and efficacy of a new medicinal 
product; which has led to creation of the ICH Guideline M4; The Common Technical 
Document (CTD); adopted in final form in November 2000. The date agreed upon 
implementation for the CTD; in all three regions; was July 2003.  
Thus; information and documents accompanying an application for approval of 
marketing authorization in any of these regions mentioned above must be submitted in 
accordance with the requirements set out in the form of  5 modules:  
Module 1 - Administrative information and prescribing information; 
Module 2 - Common technical document summaries; 
Module 3 - Information on chemical; pharmaceutical and biological features of the product; 
Module 4 – Non-clinical study reports; 
Module 5 - Clinical study reports.  
The ICH guidelines are submitted to the CHMP for endorsement. Initially EMEA 
publishes these guidelines for comments (up to 6 months); and then the final form is 
subsequently published by the European Commission in the Rules Governing Medicinal 
Products in the European Union [1]. 
 
RESULTS: 
 
The CHMP guidelines are divided into five categories [2]:  
- Quality Guidelines – include a total number of 61 guidelines; divided in the following 
categories: Active substance; Manufacture of the medicinal product; Impurities; Specifications; 
analytical procedure and analytical validation; Excipients; Packaging; Stability; Pharmaceutical 
development; Specific types of products; Herbal medicinal products.  
- Biotechnology Guidelines - include a total number of 93 guidelines; divided in 
guidelines related to a drug substance (Manufacture; Characterization and Control of the Drug 
Substance; Specifications; Comparability / Biosimilarity; Plasma-Derived Medicinal Products; 
Vaccines; Stability) and guidelines related to a drug product (Pharmaceutical Development; 
Product Information; Adventitious Agents Safety Evaluation; Viral Safety; Transmissible 
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Spongiform Encephalopathies (TSE) (Animal and Human); Creutzfeldt-Jakob Disease CJD 
related; Investigational Medicinal Products; Genetically Modified Organisms (GMOs). 
- Non-Clinical Guidelines - include a total number of 66 guidelines; divided in the 
following categories: Pharmacology; Pharmacokinetics; Toxicology (Single-Dose Toxicity; Repeat-
Dose Toxicity; Genotoxicity; Carcinogenicity; Reproductive and Developmental Toxicity; Local 
Tolerance; Other Toxicity Guidelines); General guidelines and Herbal medicinal products. 
- Clinical Efficacy and Safety - include a total number of 359 guidelines; divided in the 
following categories: Clinical Pharmacology and Pharmacokinetics; Alimentary tract and 
metabolism; Blood and blood forming organs; Blood products (including biotech alternatives); 
Cardiovascular system; Dermatological; Genito-urinary system and sex hormones; Anti-
infectives for systemic use; Anti-neoplastic and immunomodulating agents; Musculoskeletal 
system; Nervous system; Respiratory system; General Guidelines; Herbal Medicinal Products. 
- Multidisciplinary Guidelines - include a total number of 71 guidelines; divided in 
the following categories: Pediatrics; Cell therapy and tissue engineering; Vaccines; 
Biosimilar; Gene Therapy; Phamacogenomics; Miscellaneous.  
 During the development of a new medicinal product; evaluation of non-clinical safety 
represents a critical step needed to support the clinical development. From all the non-clinical 
guidelines there is one; CHMP 285/95 that summarize the requirements for non-clinical safety 
studies necessary to perform clinical trials for evaluation of medicinal products. Due to the 
importance of this guideline it was implemented as National Medicine Agency’s Scientific 
Council Decision. This guideline contains international standards for evaluation the non-
clinical safety studies with a given scope and duration; it facilitates the timely conduct of clinical 
trials and reduces the unnecessary use of animals and other resources. 
The goals of the non-clinical safety evaluation include a characterization of toxic effects 
with respect to target organs; dose dependence; relationship to exposure; and potential reversibility.  
This information is important for the estimation of an initial safe starting dose for the human trials; 
the therapeutic index and the identification of parameters for clinical monitoring of potential 
adverse effects.  The non-clinical safety evaluation in order to grant marketing authorization to a 
new investigational medicinal product contains the following types of studies [3]: 
1) Pharmacological studies  
Primary and secondary pharmacological studies that investigate primary 
pharmacodynamic effects related to proposed indications and the general pharmacological effects. 
2) Toxicokinetic and pharmacokinetic studies  
The pharmacokinetic studies investigate absorption; tissue distribution; metabolism; 
profile of metabolites; routes of excretion of the active substance and metabolites. 
The toxicokinetic studies investigate the systemic exposure and calculate the safety 
ratio of AUC in animals and humans. 
3) Toxicological studies  
The goals of the toxicological evaluation include detection of potential toxicity of the 
pharmaceuticals with special emphasis on the possible relevance to the proposed indication. 
The toxicology studies usually include: single dose toxicity studies; repeated dose 
toxicity studies; reproduction toxicity studies; genotoxicity studies; local tolerance studies and 
for medicinal products which are intended for long time use or if there is a suspicion of 
carcinogenic potential; carcinogenicity studies.  
a) Single dose toxicity studies (Acute toxicity) 
The single dose (acute) toxicity for a pharmaceutical should be evaluated in two 
mammalian species prior to the first human exposure. A dose escalation study is considered 
an acceptable alternative to the single dose design. 
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b) Repeated dose toxicity studies should be conducted in two mammalian species 
(one non-rodent); the recommended duration of this being usually related to the duration of 
the therapeutic indication and scale of the proposed clinical trial; as follows:  
Conduct of longer duration toxicity studies is recommended as given in Table 1. 
** In the US; as an alternative to the 2-week studies; single dose toxicity studies with 
extended examinations can support single-dose human trials. 
*** See. Data from 6 months of administration in non-rodents should be available 
before the initiation of the clinical trials longer than 3 months. Alternatively; if applicable; 
data from a 9-month non-rodent study should be available before the treatment duration 
exceeds that; which is supported by the available toxicity studies. 
 
Table 1 
Duration of Repeated Dose Toxicity Studies to Support Phase I and II Trials in EU and Phase I; II and III 
Trials in the US and Japan* 
 
Minimum Duration of Repeated 
Dose Toxicity Studies 
 
Duration of Clinical Trials  
Rodents Non-rodents 
Single Dose 2 Weeks** 2 Weeks** 
Up to 2 Weeks 2 Weeks** 2 Weeks** 
Up to 1 Month  1 Month 1 Month 
Up to 3 Months 3 Months  3 Months 
Up to 6 Months 6 Months***  Chronic***) 
* In Japan; if there are no Phase II clinical trials of equivalent duration to the planned Phase III trials; conduct of 
longer duration toxicity studies is recommended as given in Table 2. 
** In the US; as an alternative to 2 week studies; single dose toxicity studies with extended examinations can 
support single-dose human trials. 
*** See. Data from 6 months of administration in non-rodents should be available before the initiation of clinical 
trials longer than 3 months. Alternatively; if applicable; data from a 9 month non-rodent study should be 
available before the treatment duration exceeds that which is supported by the available toxicity studies. 
 
Table 2 
Duration of Repeated Dose Toxicity Studies to Support Phase III Trials in the EU and Marketing in all 
Regions* 
 
Minimum Duration of Repeated 
Dose Toxicity Studies 
 
Duration of Clinical Trials  
Rodents Non-rodents 
Up to 2 Weeks 1 Month 1 Month 
Up to 1 Month  3 Months 3 Months 
Up to 3 Months 6 Months  3 Months 
Up to 6 Months 6 Months Chronic*) 
* The above Table also reflects the Marketing recommendations in the 3 Regions except that a chronic nonrodent 
study is recommended for clinical use > 1 month. 
 
c) Local tolerance studies 
Local tolerance should be studied in animals using routes relevant to the proposed 
clinical administration. The evaluation of local tolerance should be performed prior to human 
exposure. The assessment of local tolerance may be part of other toxicity studies. 
d) Genotoxicity studies include in vitro and in vivo tests in order to evaluate the 
mutations and chromosomal damage and are necessary; usually prior to first human exposure; 
if an equivocal or positive finding is obtained; additional testing should be performed. 
The standard battery of tests for genotoxicity (6) should be completed prior to the 
initiation of Phase II studies. 
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e) Carcinogenicity studies 
Completed carcinogenicity studies are not usually needed in advance of the conduct of 
clinical trials unless there is a cause for concern.  
f) Reproduction toxicity studies 
Reproduction toxicity studies  should be conducted as is appropriate for the population 
that is to be exposed.  
In Pregnant women; prior to the inclusion in clinical trials; all the reproduction toxicity 
studies and the standard battery of genotoxicity tests should be conducted. In addition; safety 
data from previous human exposure are generally needed. 
 
4) Supplementary studies  
Additional non-clinical studies may be needed if previous non-clinical or clinical findings 
with the product or related products have indicated special safety concerns. 
 
DISCUSSIONS 
 
First dose in humans’ clinical trials; conducted in order to demonstrate the efficacy 
and safety of a pharmaceutical; will be performed starting with a relatively low exposure in a 
small number of subjects; followed by clinical trials in which exposure usually increases by 
dose; duration and/or size of the exposed patient population. For some new investigational 
medicinal products; the non-clinical safety pharmacology and toxicological programs can 
provide sufficient safety data for estimating risk prior to first administration in humans. 
However; for some novel medicinal products this non-clinical safety program might not be 
sufficiently predictive of serious adverse reactions in man and the non-clinical testing and the 
design of the first-in-human study requires special consideration; which involves the 
identification of the risk factors; derived from particular knowledge or lack of regarding; the 
mode of the action; the nature of the target and/or the relevance of animal models. 
The estimation of the first dose in human is an important element to safeguard the 
safety of subjects participating in first-in-human studies and all available information has to 
be taken in consideration. Different methods can be used: 
a) In general; the No Observed Adverse Effect Level (NOAEL) determined in non-
clinical safety studies performed in the most sensitive and relevant animal species; adjusted 
with allometric factors or on the basis of pharmacokinetics gives the most important 
information in estimation of the first dose in human. The relevant dose is then 
reduced/adjusted by appropriate safety factors according to the particular aspects of the 
molecule and the design of the clinical trials [4]. 
b) In exploratory studies (pre-phase I) of an early characterisation of a substance׳s 
pharmacokinetic/distribution properties or receptor selectivity profile using sensitive 
analytical techniques (positron emission tomography- PET; accelerator mass spectrometry – 
AMS; etc); a microdose is used; defined as less than 1/100th of the dose calculated to yield a 
pharmacological effect; based on primary pharmacodynamic data obtained in vitro and in 
vivo studies and at a maximum dose of 100 micrograms [5]. 
c) For some investigational medicinal products for which risk factors  were identified; 
an additional approach to dose calculation should be taken. Information about 
pharmacodynamics can give further guidance for dose selection and the ‘Minimal Anticipated 
Biological Effect Level’ (MABEL) approach is recommended. The MABEL is the anticipated 
dose level leading to a minimal biological effect level in humans. When using this approach; 
potential differences in sensitivity for the mode of action of the investigational medicinal 
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product between humans and animals; need to be taken into consideration all pharmacokinetic 
and pharmacodynamic data derived from in-vitro studies. 
When the methods of calculation (e.g. NOAEL; MABEL) give different estimations 
for the first dose in humans; the lowest value should be used [4]. 
 
CONCLUSIONS 
 
 Various requests lead to specific protocol designs for non- clinical studies. 
 Safety is the primary design concern to be taken into consideration and thoroughly 
assessed. 
 From the beginning; it is very important to design and conduct the studies considering the 
calculation of the first dose in humans; including the analysis of the risk factors for the 
substances that are developed. 
 These recommendations facilitate the timely conduct of clinical trials and reduce the 
unnecessary use of animals and other resources.  
 The rules governing medicinal products in the European Union are specified in scientific 
guidelines prepared by the Committee for Medicinal Products for Human Use (CHMP) in 
consultation with the competent authorities of the EU Member States; to help applicants 
preparing the marketing-authorization applications for medicinal products for human use. 
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